Immix Biopharma is trading 5.32% higher at $10.20, with no confirmed company-specific catalyst explaining the October 5 move.
- An October 5 report cited NXC-201 complete responses in 40 of 45 patients, without linking the results to the move.
- The S&P 500 is up 0.58% and the Nasdaq Composite 0.90%; their gains may support a risk-on backdrop but are not established as the cause.
- The prior $125 million offering is background context, not a confirmed trigger.